Catalent (CTLT)
(Delayed Data from NYSE)
$55.80 USD
-0.01 (-0.02%)
Updated May 13, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 1 - 20 ( 215 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CTLT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
1Q24 - GLP-1s Ramping as New Programs Offset Waning COVID
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department